Related Experiment Video
Updated: Nov 1, 2025

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Implantable cardioverter defibrillators in left ventricular assist device patients: Α systematic review and
Filippos-Paschalis Rorris1, Constantine N Antonopoulos1, Christos P Kyriakopoulos2
1Department of Thoracic and Cardiovascular Surgery, Evangelismos General Hospital, Athens, Greece.
Insights
Implantable cardioverter-defibrillators (ICDs) do not impact overall mortality in continuous flow left ventricular assist device (CF-LVAD) patients. However, ICDs show a trend towards improved heart transplantation success and a survival benefit in European but not US patient groups.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Implantable cardioverter-defibrillators (ICDs) are standard for preventing sudden cardiac death in heart failure.
- Guidelines conflict on ICD use in patients with continuous flow left ventricular assist devices (CF-LVADs).
Purpose of the Study:
- To evaluate the impact of ICDs on mortality and heart transplantation in CF-LVAD patients.
- To compare outcomes between US and European studies regarding ICD use in CF-LVAD patients.
Main Methods:
- Systematic review and meta-analysis adhering to PRISMA guidelines.
- Inclusion of studies comparing ICD use in CF-LVAD patients.
- Pooled odds ratios calculated for all-cause mortality and successful bridge to transplantation.
Main Results:
- ICD use was not associated with all-cause mortality in CF-LVAD patients (OR: 0.85, 95% CI: 0.64-1.12).
- A trend towards increased likelihood of successful bridge to transplantation was observed with ICDs (OR: 1.12, 95% CI: 1.0-1.3).
- European studies showed decreased mortality with ICDs (OR: 0.58), while US studies showed increased mortality (OR: 1.2).
Conclusions:
- Overall survival benefit of ICDs in CF-LVAD patients was not demonstrated.
- Significant differences in outcomes and baseline characteristics exist between US and European CF-LVAD populations.
- Further investigation into population-specific benefits of ICDs in CF-LVAD patients is warranted.
Abstract:
Implantable cardioverter-defibrillators (ICDs) remain the standard of care in advanced heart failure with reduced ejection fraction patients for the prevention of sudden cardiac death. However, current guidelines remain conflicting with respect to the use of ICDs in patients supported with a continuous flow left ventricular assist device (CF-LVAD). The current review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies comparing the use of ICD in patients with CF-LVADs were included. The 2 primary outcomes studied were all-cause mortality, and a successful bridge to heart transplantation. We calculated pooled odds ratios (ORs) with 95% confidence intervals (CIs). We also compared baseline characteristics between US and European studies, for CF-LVAD patients with an ICD. Among all studies, the use of an ICD was not associated with all-cause mortality in patients with CF-LVADs (OR: 0.85, 95% CIs: 0.64-1.12, p = 0.24). The presence of an ICD was associated with a trend towards increased likelihood of successful bridge to heart transplantation (OR: 1.12, 95% CI: 1.0-1.3, p = 0.06). A subgroup analysis of studies published by European centers revealed a significant decrease in pooled mortality (OR: 0.58, 95% CI: 0.4-0.83, p = 0.003) with the use of ICD, contrary to an increase in pooled mortality among studies published by US centers (OR: 1.2, 95% CI 1.02-1.33, p = 0.025). Moreover, we identified significant differences in baseline characteristics such as bridge to transplantation rate, Interagency Registry for Mechanically Assisted Circulatory Support profiles, and use of an intra-aortic balloon pump or extracorporeal membrane oxygenation preoperatively, between the US and European populations. While this meta-analysis did not show an overall survival benefit with the use of an ICD in CF-LVAD patients, it revealed significant differences in the derived benefit, in distinct patient populations. This might reflect differences in baseline patient characteristics and warrants further investigation.
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
16:40A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Dysrhythmias VI: Management of Dysrhythmias
Heart Failure IV: Classification and Diagnostic Evaluation